IGC Pharma, Inc. (IGC) Earnings History
Net Loss21 years of earnings data (2006–2026) · Currently unprofitable on a TTM basis
Loading earnings history...
IGC Pharma, Inc. (IGC) Earnings Overview
As of June 28, 2026, IGC Pharma, Inc. (IGC) reported trailing twelve-month net income of -$7M, reflecting +22.3% year-over-year growth. The company earned $-0.07 per diluted share over the past four quarters, with a net profit margin of -552.1%.
Looking at the long-term picture, IGC's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2007.
IGC Pharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TLRY (-$2.95B net income, -266.3% margin), SNDL (-$11M net income, -1.7% margin), ATAI (-$663M net income, -16142.0% margin), IGC has room to improve margins relative to the peer group. Compare IGC vs TLRY →
IGC Earnings vs Peers
Earnings metrics vs comparable public companies
IGC Historical Earnings Data (2006–2026)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | -$7M | +8.0% | -$10M | $-0.07 | -552.1% | -860.3% |
| 2025 | -$7M | +45.2% | -$7M | $-0.09 | -560.3% | -585.8% |
| 2024 | -$13M | -13.0% | -$10M | $-0.22 | -966.5% | -728.5% |
| 2023 | -$12M | +23.4% | -$12M | $-0.22 | -1263.0% | -1270.1% |
| 2022 | -$15M | -70.4% | -$15M | $-0.30 | -3782.4% | -3886.1% |
| 2021 | -$9M | -20.5% | -$9M | $-0.21 | -981.2% | -971.5% |
| 2020 | -$7M | -78.5% | -$7M | $-0.19 | -179.6% | -168.6% |
| 2019 | -$4M | -129.4% | -$5M | $-0.12 | -80.1% | -90.8% |
| 2018 | -$2M | +4.3% | -$2M | $-0.06 | -81.4% | -81.6% |
| 2017 | -$2M | +33.5% | -$2M | $-0.07 | -321.7% | -353.9% |
| 2016 | -$3M | +39.1% | -$3M | $-0.17 | -44.1% | -45.6% |
| 2015 | -$5M | -52.6% | -$4M | $-0.31 | -60.1% | -56.5% |
| 2014 | -$3M | -34.2% | -$3M | $-0.37 | -133.0% | -111.2% |
| 2013 | -$2M | +70.9% | -$2M | $-0.32 | -28.0% | -30.9% |
| 2012 | -$8M | +61.7% | -$8M | $-2.66 | -184.6% | -178.9% |
| 2011 | -$20M | -322.7% | -$8M | $-13.40 | -496.8% | -194.1% |
| 2010 | -$5M | -817.4% | -$4M | $-4.15 | -26.8% | -22.3% |
| 2009 | $-522,000 | +90.0% | $4M | $-0.52 | -1.5% | 10.8% |
| 2008 | -$5M | -443.5% | $5,000 | $-6.09 | -238.3% | 0.2% |
| 2007 | $2M | +442.0% | $0 | $1.09 | - | - |
| 2006 | $-443,840 | - | $136,901 | $-1.40 | -210.8% | 65.0% |
Download Data
Export IGC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IGC — Frequently Asked Questions
Quick answers to the most common questions about buying IGC stock.
What is IGC earnings per share (EPS)?
IGC trailing twelve-month (TTM) diluted EPS is $-0.07, reflecting +22.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2006 to 2026 is available in the table on this page.
What is IGC Pharma, Inc.'s net income?
IGC Pharma, Inc. (IGC) trailing twelve-month net income is $-7M as of 2026. Earnings grew +22.3% year-over-year.
Is IGC profitable?
IGC is not currently profitable on a TTM basis, reporting a net loss of $-7M. Net margin is -552.1%. Investors should monitor for a return to profitability.
What is IGC's earnings growth rate?
IGC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2006 to 2026.
What are IGC's profit margins?
IGC Pharma, Inc. net profit margin is -552.1%, operating margin is -860.3%, and gross margin is +29.7%. Below-average margins reflect competitive or cost pressures. Return on Equity is -105.2%.
Is IGC growing earnings?
Yes, IGC earnings are accelerating — EPS growth of +22.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-7M. Earnings momentum is strengthening.
What was IGC's best earnings year?
IGC Pharma, Inc.'s highest annual net income on record is $2M, achieved in fiscal year 2007. Earnings history on this page spans 2006 to 2026 and includes all annual and quarterly figures.
What were IGC's earnings last quarter?
IGC's most recent reported quarter was Q4 2026. Net income was $-2M with diluted EPS of $-0.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.